| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3904414 | Urology | 2008 | 5 Pages |
Abstract
Maximizing local control and randomized trials evaluating the impact on survival of adding novel agents to maximal local therapy are warranted in men whose prostate cancer demonstrates abnormal p53 expression.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Anthony V. D'Amico, Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff, Cancer and Leukemia Group B Cancer and Leukemia Group B,